Alimera Sciences, Inc. (NASDAQ:ALIM) has been assigned a $5.00 target price by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 218.47% from the stock’s current price.

Other equities analysts have also recently issued research reports about the stock. Rodman & Renshaw started coverage on shares of Alimera Sciences in a research report on Thursday, April 27th. They issued a “buy” rating and a $4.00 price target on the stock. Cowen and Company reaffirmed a “buy” rating and issued a $3.00 price target on shares of Alimera Sciences in a research report on Tuesday, July 11th. Zacks Investment Research raised shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Monday, July 10th. Finally, ValuEngine raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Alimera Sciences presently has an average rating of “Hold” and a consensus price target of $3.38.

Alimera Sciences (NASDAQ:ALIM) traded up 4.67% during mid-day trading on Friday, hitting $1.57. The company had a trading volume of 382,253 shares. The firm’s market capitalization is $101.89 million. Alimera Sciences has a 12-month low of $1.03 and a 12-month high of $2.40. The company’s 50 day moving average price is $1.42 and its 200-day moving average price is $1.38.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million during the quarter, compared to the consensus estimate of $10.20 million. During the same period in the previous year, the business posted ($0.17) EPS. Alimera Sciences’s revenue was up 8.3% compared to the same quarter last year. On average, analysts forecast that Alimera Sciences will post ($0.21) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/08/06/hc-wainwright-reiterates-5-00-price-target-for-alimera-sciences-inc-nasdaqalim.html.

A number of institutional investors have recently made changes to their positions in ALIM. KCG Holdings Inc. boosted its position in shares of Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares during the last quarter. Kennedy Capital Management Inc. purchased a new position in Alimera Sciences during the first quarter valued at approximately $467,000. Finally, JW Asset Management LLC boosted its position in Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares in the last quarter. 43.58% of the stock is currently owned by institutional investors and hedge funds.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.